History and exam
Your Organisational Guidance
ebpracticenet urges you to prioritise the following organisational guidance:
Opvolging en revalidatie van patiënten met aanhoudende klachten na COVID-19 in de eerste lijnPublished by: KU Leuven | Werkgroep Ontwikkeling Richtlijnen Eerste Lijn (Worel)Last published: 2023Suivi et revalidation des patients présentant des symptômes persistants après la COVID-19 en première lignePublished by: KU Leuven | Groupe de Travail Développement de recommmandations de première ligneLast published: 2023Key diagnostic factors
common
presence of risk factors
previous diagnosis of COVID-19 or history of suspected acute COVID-19 illness
Other diagnostic factors
common
fatigue/weakness
cognitive impairment (brain fog)
Reported in 12% to 35%. May include lack of concentration or attention, slower movements, poor memory, language problems, mental fatigue, and poor planning or multitasking.[88][92]
Lack of concentration was found in up to 60% of patients 4 weeks or more after COVID-19 diagnosis.[1]
Rule out dementia. Ask about drugs (including non-prescription drugs), substance misuse, and sleep disturbance.[88]
impaired sleep
Reported in 11% to 44% of patients presenting with long COVID.[80]
headache
Reported in up to 79% of patients 4 weeks or more after COVID-19 diagnosis.[1]
dizziness
Present in up to 48% of patients 4 weeks or more after COVID-19 diagnosis.[1] Determine if the symptoms are more consistent with vertigo or pre-syncope. Can be a symptom of autonomic dysfunction. Rule out vascular causes (brainstem or cerebellar stroke), vestibular conditions (e.g., vestibular neuritis, benign paroxysmal positional vertigo, or Meniere’s disease), deconditioning, dehydration, anaemia, hypoxia, anxiety, uncontrolled diabetes, lung disease, and cardiac disease, including sinus node dysfunction, myocarditis, and heart failure.[88][94] Assess for drugs that could be contributing to symptoms.
dyspnoea
Reported in 22% to 40%. Reported in 38% of patients 4-12 weeks after COVID-19 diagnosis and 22% after 12 weeks or more.[1] More likely in patients with more severe initial COVID-19. Patients who did not experience hypoxaemia or require hospitalisation are less likely to have post-acute pulmonary function problems or imaging abnormalities.[88]
Differentiate between dyspnoea at rest or with movement or on exertion. Rule out urgent considerations, such as pulmonary embolism and urgent cardiovascular causes of breathlessness.[88]
cough
anosmia/dysgeusia
Anosmia/dysgeusia is present in up to 46% of patients 4 weeks or more after COVID-19 diagnosis.[1] Consider an altered sense of smell and taste as well as an absence of it, and whether the patient is experiencing any smells that are not really present (phantosmia). Rule out sinus disease and rhinitis.
pain (including arthralgias and myalgias)
Reported in 9% to 19% of patients with long COVID.[80] Use a scale to determine the severity.
chest pain
post-exertional malaise
anxiety/depression
palpitations
Can be a symptom of autonomic dysfunction. Rule out deconditioning, dehydration, anaemia, hypoxia, anxiety, lung disease, and cardiac disease, including sinus node dysfunction, myocarditis, and heart failure.[88]
thirst/dry mouth
May be related to underlying autonomic dysfunction. Also consider a possible underlying rheumatological disorder or a drug adverse effect.[87]
loss of sexual drive or capacity
Possibly related to co-existing fatigue, pain, neurocognitive issues, neuropathy, and cardiovascular dysfunction. Evaluate for possible hypogonadism, diabetes, or cardiopulmonary dysfunction.[80]
numbness/tingling
hair loss
New-onset hair loss may be due to telogen effluvium from the initial cytokine storm.[97]
gastrointestinal symptoms
Risk factors
strong
severe COVID-19 illness (requiring hospitalisation or ICU admission)
People with severe COVID-19 illness who were hospitalised and/or admitted to the intensive care unit (ICU) have a significant risk of developing long COVID (odds ratio [OR] 2.37 and 2.48, respectively).[42] A population-based study in Sweden found the proportion of people receiving a long COVID diagnosis to be 1% among those not hospitalised, 6% among those hospitalised, and 32% among those treated in the ICU.[63] Of note, the pathophysiology of ongoing symptoms following severe or critical acute COVID-19 illness may be distinct from the pathophysiology of long COVID in people with mild, acute COVID-19. Instead, ongoing symptoms in people with severe acute COVID-19 may be more typical of post-intensive care syndrome.[43] See Differentials.
not vaccinated or only partially vaccinated against COVID-19
weak
age >40 years
People older than 40 years have a higher risk of developing long COVID compared with adults younger than 40 years (OR 1.21).[42]
BMI >30 kg/m²
smoking
Current smoking status is associated with a higher risk of developing long COVID (OR 1.10).[42]
anxiety/depression
Comorbid anxiety or depression are associated with a higher risk of developing long COVID (OR 1.19).[42]
asthma
Comorbid asthma is associated with a higher risk of developing long COVID (OR 1.24).[42]
chronic kidney disease
Comorbid chronic kidney disease is associated with a higher risk of developing long COVID (OR 1.12).[42]
chronic obstructive pulmonary disease (COPD)
Comorbid COPD is associated with a higher risk of developing long COVID (OR 1.38).[42]
diabetes
Comorbid diabetes is associated with a higher risk of developing long COVID (OR 1.06).[42]
immunosuppression
Immunosuppression is associated with a higher risk of developing long COVID (OR 1.50).[42]
ischaemic heart disease
Comorbid ischaemic heart disease is associated with a higher risk of developing long COVID (OR 1.28).[42]
Use of this content is subject to our disclaimer